


BIOTECHNOLOGY

FROM IDEA TO MARKET



Fred Mermelstein, Richard Prince,
and Carl Novina

Editors

Biotechnology

From Idea to Market

Edited by
Fred Mermelstein, Richard Prince
and Carl Novina

To order this book, please visit: go.pda.org/BIOTECH

PDA
Bethesda, MD, USA
DHI Publishing, LLC
River Grove, IL, USA

10 9 8 7 6 5 4 3 2 1

ISBN: 978-1-942911-37-1

**Copyright © 2019 Fred Mermelstein, Richard Prince and Carl Novina
All rights reserved.**

All rights reserved. This book is protected by copyright. No part of it may be reproduced, stored in a retrieval system or transmitted in any means, electronic, mechanical, photocopying, recording, or otherwise, without written permission from the publisher. Printed in the United States of America.

Where a product trademark, registration mark, or other protected mark is made in the text, ownership of the mark remains with the lawful owner of the mark. No claim, intentional or otherwise, is made by reference to any such marks in the book. Websites cited are current at the time of publication. The authors have made every effort to provide accurate citations. If there are any omissions, please contact the publisher.

While every effort has been made by the publisher and the authors to ensure the accuracy of the information expressed in this book, the organization accepts no responsibility for errors or omissions. The views expressed in this book are those of the authors and may not represent those of either Davis Healthcare International or the PDA, its officers, or directors.



Connecting People, Science and Regulation®



This book is printed on sustainable resource paper approved by the Forest Stewardship Council. The printer, Gasch Printing, is a member of the Green Press Initiative and all paper used is from SFI (Sustainable Forest Initiative) certified mills.

PDA Global Headquarters

Bethesda Towers, Suite 150
4350 East-West Highway
Bethesda, MD 20814
United States
www.pda.org/bookstore
001-301-986-0293

Davis Healthcare International Publishing, LLC

2636 West Street
River Grove
IL 60171
United States
www.DHIBooks.com

CONTENTS

Foreword	xv
<i>Phillip A. Sharp</i>	
Introduction	xix
<i>Fred Mermelstein, Richard Prince and Carl Novina</i>	
Acknowledgements	xxv
Editors	xxix
Contributors	xxxiii

SECTION I DUE DILIGENCE

I FIRST PRINCIPLES OF R&D	
– THE ROLE OF DUE DILIGENCE	3
<i>Fred Mermelstein</i>	
Unmet Medical Need	4
Intellectual Property: Exclusivity and Freedom to Operate	11
Pricing and Reimbursement	22

Additional Elements of Due Diligence	27
FDA Regulatory Process	33
Manufacturing	35
Financial	37
The Management Team	40
What Due Diligence Can't Uncover	41
Conclusion	41
References	42
About the Author	43
2 TRANSLATIONAL RESEARCH IN ACADEMIA – MOVING TOWARDS THE D SIDE OF R&D	45
<i>Carl D. Novina</i>	
Introduction: An Integrated Approach to Basic and Translational Research	45
Why Participate in Translational Research?	48
How to Integrate Basic and Translational Research	56
Academic Institutional Support for Translational Research Programs	71
Conclusion	78
References	79
About the Author	83
3 THE TARGET PRODUCT PROFILE SHEET – AN INVALUABLE TOOL IN R&D PLANNING	85
<i>Shani C. Missner and Matthew R. Weinberg</i>	
Introduction	85
Purpose of a TPP	86
The TPP Process	86
Regulatory Outlook	88
Benefits of a TPP	89
The Use of a TPP Early in Drug Development	90
Defining the Regulatory Value of a TPP	90
Quality Target Product Profile	91
The Strategic Evaluation Framework	92
Go/No-Go in the Strategic Evaluation Framework	95
TPP Scenarios	102
Conclusion	102
Appendix I Target Product Profile Template	103
References	107
About the Authors	110

4	FOUNDING A BIOTECHNOLOGY COMPANY	111
	<i>Alan Crane</i>	
	Introduction	111
	The Biotechnology Company Birthing Process	112
	Key Success Factors	138
	References	145
	About the Author	146
5	MEDICAL DEVICES – FROM IDEA TO MARKET	147
	<i>John Butziger and Laurie Bourgeois</i>	
	Introduction	147
	Regulatory Overview	149
	Selecting Partners for your Needs	152
	Partner Proposals	156
	A Note on Intellectual Property	157
	Quality Management System	157
	Document Control System	159
	Design Controls	160
	Program Phases	162
	Project Set-Up	164
	Hazard and Risk Analysis	166
	Device Design	167
	Design Verification Testing	171
	Design Validation Testing	175
	Regulatory Submittal	176
	Process Development	177
	Process Validation	181
	Production Transfer	185
	Production	186
	Contracts/Agreements	188
	References	190
	About the Authors	192
6	HOW TO COMPOSE A BUSINESS PLAN	195
	<i>Douglas A. Hamilton</i>	
	Introduction	195
	Start with the Table of Contents	198
	Sample Table of Contents for Biotechnology Company	
	Business Plan	198
	Executive Summary	200
	Company Overview	200

Research and Development Section	201
Marketing Section	217
Intellectual Property Section	231
Manufacturing Plan Section	232
Financial Strategy in Financial Information Section	236
Management Section	248
References	248
About the Author	251

SECTION 2 FINANCING

7 CORPORATE COMMUNICATIONS – EXECUTIVE SUMMARIES AND PITCH DECKS	255
<i>Dian Griesel</i>	
The Investing Equation	257
Here's What an Investor is Seeking	257
Refining Your Pitch	266
Motivating Action	267
Healthcare Company Questions	270
Conclusion: Final Thoughts About Asking for the Money	277
About the Author	279
8 FINANCING BIOTECHNOLOGY START-UPS – THE ROLE OF THE LICENSED BROKER DEALER	281
<i>Jeff Eliot Margolis</i>	
Introduction	281
Essentials	282
Types of Financings	283
Identifying Categories of Investors	287
Finding and Qualifying Potential Investors	290
Value of Strategic Transactions as Financing Vehicles and More	294
Private versus Public Financings – Private versus Public Companies	295
Managing the Communications Process with Investors	297
Conclusion	298
References	298
About the Author	298

9	INDUSTRY PARTNERSHIPS AND LIQUIDITY EVENTS – ENGAGING WITH BIG PHARMA	301
	<i>David R. Boyko</i>	
	Corporate Partnering	302
	Liquidity Events	315
	References	325
	About the Author	327
 SECTION 3 OPERATIONALIZATION		
10	REGULATORY AFFAIRS’ ROLE IN PRODUCT DEVELOPMENT	331
	<i>David L. Rosen</i>	
	It’s the Law: The Why and the How	331
	Regulatory Affairs: The Architect, Interpreter and Advocate	340
	The Big Pieces: You Can’t Get There Without Them	343
	Globalization: Don’t Leave Anything on the Table	349
	Ready to Launch: Preparing the Beachhead	354
	Maintenance: The Party is Just Getting Started	358
	References	361
	About the Author	366
11	CLINICAL TESTING OF BIOSIMILARS	369
	<i>Sarfaraz K. Niazi</i>	
	Introduction	369
	Overarching Guidance	371
	Clinical Pharmacology Studies	374
	Interchangeability	390
	Comparative Clinical Studies	396
	Case Studies	404
	Appendix 1 New Drug Discovery	409
	Appendix 2 Data From Completed Studies	421
	Appendix 3 Biosimilar Clinical Trials	423
	References	448
	About the Author	454

12	SAFEGUARDING CLINICAL DEVELOPMENT – STRATEGIC AND QUALITY CONSIDERATIONS	455
	<i>Richard Prince</i>	
	Principle #1 – Corporate Governance and Executive Management	473
	Principle #2 – Science	475
	Principle #3 – Design	477
	Principle #4 – Measurement	481
	Principle #5 – Independence (As Part of Teamwork)	484
	Summary	485
	References	487
	About the Author	490
13	PERFORMING CLINICAL TRIALS – THE ROLE OF CLINICAL OPERATIONS	491
	<i>Cassandra Erato and Angela Bartkus</i>	
	Starting Your Clinical Trial, Moving from Animals to Humans	491
	Early Stages of a Clinical Trial Program	491
	Clinical Trial Types	494
	What to Look for in a CRO for an Early Stage Trial	498
	Regulatory Considerations in a Phase I Trial	501
	Trial Lifecycle and Project Management	506
	The Importance of Data Automation	519
	References	519
	About the Authors	520
14	DESIGNING AND BUILDING A BIOTECHNOLOGY FACILITY	523
	<i>Kim Nelson</i>	
	Introduction	523
	Quality Risk Management	526
	Project and Facility Design Risk Assessments	527
	cGMP Compliance	529
	Biosafety and Biocontainment	533
	ISPE Baseline® Guides	537
	Cleanroom HVAC Classifications	539
	Design and Operational Paradigms	541
	Concurrent versus Campaigned Multiproduct Operations	542
	Bioburden Control versus Aseptic Processing	544

Process Closure: Closed Systems versus Open Processing	544
Room Segregation versus Closed Systems	545
Single-Use Technology versus Stainless Steel Equipment	547
Minimizing Classified Environments and Placing Equipment in Gray/Mechanical Spaces	553
Corridor System and cGMP Flows: Unidirectional versus Mono-Corridor	554
Gowning Strategy	557
Air-Locking Strategies	557
Reliability and Redundancy of Electrical and Utility Systems	558
Process Intensification	560
Staging Space in Single-use Facilities	561
Solid Waste Management in Single-use Systems Facilities	561
Outsourcing versus Fully Integrated Biopharmaceutical Operations	562
Modular/“Podular” Construction Approaches	563
Flexible and Agile Facilities	564
Conclusion	565
References	567
About the Author	570
15 MANUFACTURING BIOPHARMACEUTICALS – FROM START-UP TO COMMERCIALIZATION	573
<i>Joseph Waggett and Laura Grayson Roselli</i>	
Introduction	573
Differences Between Drugs and Biologics	576
Process Design/Development (Recombinant Protein Biopharmaceuticals)	579
QTPP and Identification of CQAs and CPPs	582
Process Design and Process/Product Characterization for a Biopharmaceutical Product	583
Scale-up and Process Validation	583
Commercial Manufacturing	589
Cell Therapy, Gene Therapy and Personalized Medicines	598
References	602
Recommended Reading	604
About the Authors	608

16	QUALITY CONTROL TESTING THROUGHOUT THE PRODUCT DEVELOPMENT LIFECYCLE	609
<i>Daniel Prince, Martell Winters and Richard Prince</i>		
Research and Development Programs	613	
Early Stage Development	613	
Late Stage Development	615	
Commercial Testing	615	
Selecting a Contract Testing Organization	617	
Designing QC Testing Programs	623	
Test Method Qualification vs. Test Method Validation	627	
Test Method Qualification	628	
Test Method Verification	629	
Test Method Validation	630	
Test Article Categories	631	
Specialized Validation Testing	635	
The Lifecycle of Contracted Testing Services	637	
The Future of QC Laboratories	638	
References	638	
About the Authors	641	
SECTION 4 LEGAL		
17	FORMING THE ENTERPRISE AND RAISING CAPITAL	645
<i>Travis L. Gering</i>		
Introduction and General Caveats	645	
Choice of Entity	646	
Federal and State Laws Governing the Issuance of Securities	657	
Types of Securities	659	
Private Placements	662	
Exemptions from Securities Act Registration	663	
Securities Act Section 4(a)(2)	664	
Regulation D	668	
Regulation S	682	
Crowdfunding	682	
Regulation A+	687	
Rule 701 Exemption for Employee Option Plans and Incentive Plans	693	

Securities Act Rule 144	694
Rule 144A Offerings	698
Cryptocurrencies and Initial Coin Offerings	699
Going Public	702
The Integration Doctrine	710
Intrastate Offering Exemptions: Rules 147 and 147A	711
Brokers, Placement Agents and Underwriters	712
Liability Considerations	720
Special Considerations for Financing Cannabis Enterprises	727
Conclusions	730
About the Author	731
18 ESTABLISHING EFFECTIVE INTELLECTUAL PROPERTY PROTECTION	733
<i>Christine Willgoos, John P. Dillon and Jonathan S. Caplan</i>	
Introduction	733
Patents and Patentability	736
Trade Secrets	772
Best Practices for a Biotechnology Company –	
Policies and Procedures for Obtaining and Protecting	
Intellectual Property	777
Conclusion	791
Appendix A U.S. Patent 5,225,539	792
References	805
About the Authors	808
19 LICENSING TECHNOLOGY FROM ACADEMIA AND GOVERNMENT	811
<i>Lita Nelsen</i>	
Introduction: What Does the TTO Do?	812
What you should Know as an Inventor	814
Acquiring a License from a University:	
For Biotech Founders and Investors	824
Sponsoring Research at the University:	
Important Terms of the Agreement	840
Appendix 1 Exclusive Patent License Agreement	845
Appendix 2 Sample University Agreement	879
About the Author	891

SECTION 5 COMMERCIALIZATION

20	UNDERSTANDING DRUG PRICING AND REIMBURSEMENT	895
<i>Joshua P. Cohen</i>		
	Fourth Hurdle Challenges to Market Access	895
	Prescription Drug Supply Chain	896
	Pharmacy Benefit Managers	898
	Central Role of Rebates	902
	Government Program Special Discounts and Rebates	904
	Pricing of Branded Single Source Products	905
	Pricing of Competing Branded Products	907
	Markets for Generic Drugs and Biosimilars	908
	Pricing and Formulary Management of Outpatient Versus Physician-Administered Drugs	909
	Pricing Determination and Transparency	910
	US Drug Prices in an International Context	911
	R&D's Relationship to Price	912
	Disconnect Between Price and Value	912
	New Pricing Policy Initiatives	914
	Concluding Remarks	916
	References	917
	About the Author	920
21	GUIDANCE TO PHARMACEUTICAL PRODUCT LAUNCH TIMELINES AND POST MARKET ORGANIZATIONAL EXPANSION	921
<i>Charles Bell, Suzanne LoGalbo and Elise Fellner Roth</i>		
	Pharmaceutical Lifecycle Management	922
	Pre-launch Timeline Activities	922
	Expansion of the Business – Three Case Studies	925
	Conclusion	935
	About the Authors	935

22	PORTFOLIO MANAGEMENT OF CORPORATE ASSETS	937
<i>Douglas A. Hamilton</i>		
What is Portfolio Management at Biopharmaceutical Companies?	937	
Why do Companies Conduct Portfolio Management?	938	
When do Companies Typically Conduct Portfolio Analysis?	939	
What do Companies use Portfolio Management For?	940	
What Type of R&D Projects are Evaluated in Portfolio Management?	941	
Overview of the Portfolio Management Process	942	
Asset Evaluation: R&D Assessment	943	
Probability Adjusted Present Value (PV) of R&D Cost to Develop	946	
Asset Evaluation: Commercial Assessment	948	
Portfolio Analysis	954	
Conclusion	965	
References	965	
About the Author	966	
GLOSSARY	969	
INDEX	1021	